A First for Parexel
The first multipurpose cGMP contract manufacturing facility in South Korea, the Korea Biotechnology Commercialization Center (KBCC), will be validated by Parexel International.
The first multipurpose cGMP contract manufacturing facility in South Korea, the Korea Biotechnology Commercialization Center (KBCC), will be validated by Parexel International. As part of an agreement with the Korea Institute of Industrial Technology (KITECH), Parexel Consulting will provide KBCC with a team of on-site validation engineering consultants and regulatory experts to train KBCC personnel, and validate the manufacturing facility, its utilities and process equipment.
"Parexel Consulting's experts will collaborate with KITECH management to position the KBCC manufacturing facility to meet or exceed current FDA and cGMP standards, thus providing a regulatory compliant foundation for future therapies to achieve regulatory approval," said Kurt A. Brykman, president of Parexel Consulting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
